Checking Heart Scans for Dangerous Rhythm Risk in Inherited Heart Disease
Uses heart mapping and MRI to find who with inherited heart disease faces dangerous rhythms.
Key facts
- Who runs it
- Vanderbilt University Medical Center
- Where
- Nashville, United StatesSee the site
- Trial code
- Registry title
- Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 13 Dec 2023
- Expected to end
- Dec 2029
- Type of study
- Observational, 3 groups
- Record updated
- 6 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who were diagnosed with atrial fibrillation, frequent extra heartbeats from the lower chambers (PVCs) or ventricular tachycardia before age 60. They must be scheduled for a catheter ablation.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Diagnosed with AF, frequent PVCs or VT before age 60, and scheduled for catheter-based AF, PVC or VT ablation.
- Earlier treatment
- No previous PVC or VT ablation.
- Biomarker or test result
- A pathogenic or likely pathogenic variant in TTN or another cardiomyopathy gene (cases), or a genotype-negative result (controls).
Main reasons for not taking part
- Already diagnosed with a genetic cardiomyopathy or arrhythmia syndrome before the ablation
- Previous PVC or VT ablation
- LVEF below 20%
- Prosthetic mitral or aortic valve
- Prior myocardial infarction
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Adults aged 18 and older
- Diagnosed with AF, frequent PVCs, or VT before age 60
- Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation
- Able to provide written, informed consent
- P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control
Who cannot take part
- Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure
- Previous PVC or VT ablation
- Prior myocardial infarction
- LVEF <20%
- VUS in 'possibly pathogenic' subgroup (control group only)
- Prosthetic mitral or aortic valve
- Contraindication to heparin
Where in United States
- Vanderbilt University Medical CenterNashville, United StatesContact: Dakota Graherr, RNTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to determine if electrophysiologic mapping and cardiac MRI can help identify patients that have genetic forms of cardiomyopathy that are at high risk for development of dangerous ventricular arrhythmias.
Read full original descriptionShow less
The investigators aim to study:
1. the prevalence and mechanism of inducible ventricular tachycardia 2. pace-mapping to define the site of origin of ventricular arrhythmias 3. voltage mapping to define low voltage scar substrate in the basal LV to determine the risk of development of ventricular arrhythmias in patients with genetic forms of cardiomyopathy.
Participants will undergo cardiac MRI before their scheduled procedure and voltage mapping during their scheduled procedure as part of data collection.
The 3 groups in the trial
- TTN-positive
Patients with a pathogenic or likely pathogenic variant in TTN on clinical genetic testing.
- Gene-positive
Patients with a pathogenic or likely pathogenic variant in a gene other than TTN on clinical genetic testing.
- Gene-negative
Patients without a pathogenic or likely pathogenic variant in a cardiomyopathy or arrhythmia gene on clinical genetic testing.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation
- Plain-language title
- Checking Heart Scans for Dangerous Rhythm Risk in Inherited Heart DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 May 2026